JAZZ Venture Partners reposted this
A fantastic milestone achieved by Swing Therapeutics, Inc. developing clinically validated software solutions to support patients suffering from Fibromyalgia, now available at Swing Care.
We’re thrilled to announce the publication in The Lancet of data from the Phase 3 trial of Stanza, a digital therapy for #fibromyalgia symptoms. This research validates Stanza’s clinical benefits for people with fibromyalgia, including improvements in well-being (measured by Patient Global Impression of Change), fibromyalgia severity (measured by the Revised Fibromyalgia Impact Questionnaire (FIQ-R)), and major fibromyalgia symptoms including pain intensity, pain interference, fatigue, sleep disturbance, depression and physical function, when compared to an active control. “Fibromyalgia options are typically limited to a handful of pharmacological interventions that have limited efficacy and that can come with difficult to manage side effects,” said Mike Rosenbluth, CEO of Swing. “This publication validates Stanza as a guideline-directed, non-drug approach that many patients previously couldn’t access, due to few available trained clinicians, geographic limitations, and cost. Read the full release: https://lnkd.in/gfTCrFCU Stanza is now available by prescription through Swing Care, a specialty clinic that offers comprehensive treatment for fibromyalgia. To learn more about Swing Care, visit www.swing.care